157 related articles for article (PubMed ID: 28265350)
1. Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy.
Codecasa LR; Toumi M; D'Ausilio A; Aiello A; Damele F; Termini R; Uglietti A; Hettle R; Graziano G; De Lorenzo S
J Mark Access Health Policy; 2017; 5(1):1283105. PubMed ID: 28265350
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK.
Wolfson LJ; Walker A; Hettle R; Lu X; Kambili C; Murungi A; Knerer G
PLoS One; 2015; 10(3):e0120763. PubMed ID: 25794045
[TBL] [Abstract][Full Text] [Related]
4. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China.
Fan Q; Ming WK; Yip WY; You JHS
Int J Infect Dis; 2019 Jan; 78():44-49. PubMed ID: 30342251
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.
Diel R; Hittel N; Schaberg T
Respir Med; 2015 May; 109(5):632-41. PubMed ID: 25862597
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea.
Park HY; Ku HM; Sohn HS; Seo HS; Yung Lee H; Hwa Lim K; Kwon JW
Clin Ther; 2016 Mar; 38(3):655-67.e1-2. PubMed ID: 26907504
[TBL] [Abstract][Full Text] [Related]
8. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
[TBL] [Abstract][Full Text] [Related]
9. Interim Effectiveness and Safety Comparison of Bedaquiline-Containing Regimens for Treatment of Diabetic Versus Non-Diabetic MDR/XDR-TB Patients in China: A Multicenter Retrospective Cohort Study.
Shi L; Gao J; Gao M; Deng P; Chen S; He M; Feng W; Yang X; Huang Y; He F; Hu Y; Lei L; Li X; Du J; Hu X; Liu Z; Tang P; Han J; Wang H; Han Y; Shu W; Sun Y; Pei Y; Liu Y
Infect Dis Ther; 2021 Mar; 10(1):457-470. PubMed ID: 33515206
[TBL] [Abstract][Full Text] [Related]
10. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres.
Riccardi N; Alagna R; Saderi L; Ferrarese M; Castellotti P; Mazzola E; De Lorenzo S; Viggiani P; Udwadia Z; Besozzi G; Cirillo D; Sotgiu G; Codecasa L;
BMC Infect Dis; 2019 Jun; 19(1):564. PubMed ID: 31253115
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
[TBL] [Abstract][Full Text] [Related]
12. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
Kunkel A; Cobelens FG; Cohen T
PLoS Med; 2016 Oct; 13(10):e1002142. PubMed ID: 27727274
[TBL] [Abstract][Full Text] [Related]
13. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B;
Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China.
Xu CH; Qiu YP; He ZL; Hu DM; Yue X; Chen ZD; Xu YY; Zhao YL
Biomed Environ Sci; 2023 Jun; 36(6):501-509. PubMed ID: 37424243
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy.
Aiello A; D'Ausilio A; Lo Muto R; Randon F; Laurenti L
J Mark Access Health Policy; 2017; 5(1):1393308. PubMed ID: 29201288
[No Abstract] [Full Text] [Related]
16. Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience.
Skrahina A; Hurevich H; Falzon D; Zhilevich L; Rusovich V; Dara M; Setkina S
Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S62-S63. PubMed ID: 28043617
[TBL] [Abstract][Full Text] [Related]
17. Cost of multi drug resistance tuberculosis in Germany.
Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
[TBL] [Abstract][Full Text] [Related]
18. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of treating multidrug-resistant tuberculosis.
Resch SC; Salomon JA; Murray M; Weinstein MC
PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
[TBL] [Abstract][Full Text] [Related]
20. Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.
D'Ambrosio L; Centis R; Tiberi S; Tadolini M; Dalcolmo M; Rendon A; Esposito S; Migliori GB
J Thorac Dis; 2017 Jul; 9(7):2093-2101. PubMed ID: 28840010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]